Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
... USA, is one of several Siemens Corporate Technology research and development centers worldwide. Since it was founded in 1977, its employees have
transformed research into practical, innovative solutions and services to support Siemens broad range of businesses. Launched in 1999 as an SCR subsidiary, ...
UK Must Maintain its Momentum in Stem Cell Expertise
... announcement
is extremely important news for victims of stroke. At the end of the day
lives - and the future of medicine in this area -- could be
transformed by
this science."
NOTES TO EDITORS
About Excalibur
Excalibur was launched in April 2008 following the acquisition of MVIL ...
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
... activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is
transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the ...
Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
... to reach important clinical milestones faster."
Gleevec(R) (imatinib mesylate) tablets* is the standard treatment for Ph+ CML and rapidly
transformed the treatment of CML when it was introduced in 2001. An ongoing Phase III trial called ENESTnd (Evaluating Nilotinib Efficacy in Clinical Trials of ...
Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)
... which are associated with poor prognoses. Responses were observed across all patients including those with poor risk cytogenetics, those whose AML
transformed from MDS, or those who developed AML after previous treatment for cancer. The results presented at ASH provide additional support for the ongoing ...
Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
... meet market requirements."
About Debio 9902 SR (ZT-1)
Debio 9902 SR is a novel acetylcholinesterase (AChE) inhibitor,
administered monthly. It is
transformed non-enzymatically into its active
compound, huperzine A (hup A). Hup A has been used in China for centuries
to treat distinct disorders such as ...
Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
... of the SGE containing vectors.
Selexis Genetic Elements(TM) based vectors have been shown to significantly
increase the population of independently
transformed cells stably
expressing the gene of interest at very high levels. Selexis Genetic
Elements(TM) are available for out-license.
About Selexis SURE ...
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
... and appeared to behave identically
to untreated T-cells except that they were resistant to infection by HIV.
ZFN treated primary CD4 T-cells and
transformed CD4 cell lines resisted
infection with R5-tropic HIV (virus that uses the CCR5 co-receptor to enter
cells), resulting in enrichment of ZFN- generated ...
Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
... activated within the body; when it comes
into contact with a naturally occurring protein called thymidine
phosphorylase, or TP, Xeloda is
transformed into 5-FU, a cytotoxic
(cell-killing) drug. Because many cancers have higher levels of TP than
does normal tissue, more 5-FU is delivered to the ...
Pew Commission Says Industrial Scale Farm Animal Production Poses 'Unacceptable' Risks to Public Health, Environment
... officials, but with this transition comes
significant change including public health threats.
The industrialization of American agriculture has
transformed the
character of agriculture itself and, in so doing, the face of rural
America. The family-owned farm producing a diverse mix of crops and ...
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
... activated within the body; when it comes
into contact with a naturally occurring protein called thymidine
phosphorylase, or TP, Xeloda is
transformed into 5-FU, a cytotoxic
(cell-killing) drug. Because many cancers have higher levels of TP than
does normal tissue, more 5-FU is delivered to the ...
Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
... strengthens Roche's leadership in oncology", said
William M. Burns, CEO, Roche Pharmaceuticals Division. "While innovative
medicines have undoubtedly
transformed cancer treatment, cancer remains a
major cause of death and we are committed to investing in the development
of new treatment options. In addition, ...
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
... negotiations with potential
partners," said Howard W. Robin, President and CEO of Nektar. "Fortunately,
over the past year Nektar has significantly
transformed its business,
moving away from inhaled insulin. We have made great progress expanding our
research efforts and have built a deep pipeline of novel ...
Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
... activated within the body; when it comes
into contact with a naturally occurring protein called thymidine
phosphorylase, or TP, Xeloda is
transformed into 5-FU, a cytotoxic
(cell-killing) drug. Because many cancers have higher levels of TP than
does normal tissue, more 5-FU is delivered to the ...
deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
... finding in several European, US, and Canadian cohorts. "With the launch of deCODE MI, we have taken another of our
breakthroughs in genetics and
transformed it into a new tool in the fight
to prevent heart attack. While many risk factors for heart attack are
understood, the disease remains the leading ...
FASgen Announces Significant Milestone in Its Cancer Drug Development Program
... the last 15 years have discovered that the mechanism acts
differently. As cancer cells do not produce fat, the fatty acid
biosynthesis pathway in the
transformed cell acts to regulate the energy
source that keeps the cell alive. One critical enzyme in that pathway is
FAS. The Company's researchers have ...
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
... activated within the body; when it comes
into contact with a naturally occurring protein called thymidine
phosphorylase, or TP, Xeloda is
transformed into 5-FU, a cytotoxic
(cell-killing) drug. Because many cancers have higher levels of TP than
does normal tissue, more 5-FU is delivered to the ...
Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
... Dr. Brown was Chairman and CEO of
MetPath, Inc., which offered a full range of clinical laboratory services
to physicians and hospitals. Dr. Brown
transformed MetPath into the largest
clinical laboratory in the world with over 3,000 employees and secured its
position on the American Stock Exchange. MetPath ...
Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
... activated within the body; when it comes
into contact with a naturally occurring protein called thymidine
phosphorylase, or TP, Xeloda is
transformed into 5-FU, a cytotoxic
(cell-killing) drug. Because many cancers have higher levels of TP than
does normal tissue, more 5-FU is delivered to the ...
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
... activated within the body; when it comes
into contact with a naturally occurring protein called thymidine
phosphorylase, or TP, Xeloda is
transformed into 5-FU, a cytotoxic
(cell-killing) drug. Because many cancers have higher levels of TP than
does normal tissue, more 5-FU is delivered to the ...
New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
... development can present a frustrating conundrum for
medical researchers. The discovery of a new compound, which may well
possess the qualities to be
transformed into a new drug, requires further
substantial investment to properly demonstrate its potential. At this
point, research organisations operating on ...
Cypher Sirolimus-eluting Coronary Stent Had Similar Results to
Bypass Surgery in Long-Term Study of Patients With Multi-Vessel
Coronary Artery Disease
... difference
between the CYPHER(R) Stent arm and the BMS arm reached statistical
significance (p=0.004).
"More than 25 years ago, balloon angioplasty
transformed the
treatment paradigm for patients with coronary artery disease," said
David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical
Officer, Cordis ...
Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor
Activity of Natural Killer Cells
... stimulated with the active metabolite of ANA773
increased NK cell cytotoxicity and cytokine secretion against both
K562 erythroleukemic cells and
transformed B cell lines. These in
vitro effects were reduced by neutralization of IFN-alpha,
confirming the role of cytokines induced by the TLR7 agonist in ...
Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to
Bypass Surgery and Better Outcomes Than Bare Metal Stents in
Subgroup Analysis of Diabetic Patients With Multivessel Coronary
Disease
... between the CYPHER(R) Stent arm
and the BMS arm reached statistical significance (p <
0.001).
"Close to 30 years ago, balloon angioplasty
transformed the
treatment paradigm for patients with coronary artery disease," said
David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical
Officer, ...
8-Year Long-term Data Demonstrate Prolonged Overall Survival and
Length of Disease Remission with Bexxar
... Iodine I 131
Tositumomab) is indicated for the treatment of patients with CD20
antigen-expressing relapsed or refractory, low-grade, follicular,
or
transformed NHL, including patients with Rituximab-refractory
NHL.
Determination of the effectiveness of the BEXXAR Therapeutic
Regimen is based on overall ...
Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease
... .
About Debio 9902
Debio 9902 is a novel acetylcholinesterase (AchE) inhibitor that
is
transformed non-enzymatically into its active compound: Hup A.
Hup A has been used in China for centuries to treat distinct
disorders such as memory loss, ...
New Data Presented on Micardis (Telmisartan) Tablets in
Hypertensive Patients With Type 2 Diabetes
... vs. 20% with losartan (p= 0.0284).(1)
At baseline proteinuria was similar for both groups. The change
from baseline after 12 months (log
transformed Urinary Protein
creatinine ratio) was 0.71 for Micardis (telmisartan) vs. 0.80 for
losartan (p=0.0284)(1) [Micardis (telmisartan) 0.71 (95% CI; ...